Evidence of successful additive autophagy activation by co-treatment with the mTOR-dependent rapamycin and mTOR-independent trehalose in a PD mouse model was recently reported [232], suggesting the efficacy of non-toxic low-dose, long-term combination treatments. This evidence concerns the gene MTOR and Parkinson disease.